This session will review ongoing advances in the management of thyroid cancers in the context of basic science discovery about their mutational makeup, evolving research on best practices and multidisciplinary treatment options, and advanced diagnostic and surgical techniques.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.
Upon completion of this activity, participants should be able to do the following:
- Describe the current state of fine needle technologies and apply currently available tools for diagnosis.
- Identify at least two major molecular alterations that have been shown to be highly prognostic in thyroid cancer.
- Integrate multimodal therapies (surgery, radioactive iodine, external beam radiation, chemotherapy, targeted therapy) to make a treatment plan for a complex individual thyroid cancer patient.
Nabil Saba, MD, FACP, is employed by Emory University and has no financial relationships with a commercial interest.
Jennifer Sipos, MD, is employed by The Ohio State University and has no financial relationships with a commercial interest.
Saad Khan, MD, is employed by UT Southwestern and has no financial relationships with a commercial interest.
Mark Zafereo, MD, FACS, is employed by MD Anderson Cancer Center and has research grants from Eli Lily and Merck and is on the board of directors of the American Academy of Otolotaryngology: head and Neck Surgery and the International Thyroid Oncology Group
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.